Alkermes plc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Alkermes plc. (ALKS) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $2.71 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-02-25
- Alkermes plc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $2.71M.
- Alkermes plc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was -$1.95M.
- Alkermes plc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was -$159.50M, a 14573.32% decline from fiscal 2022.
- Alkermes plc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $1.10M.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 9 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $2.71M 10-K · filed 2026-02-25 | ||
| 2024-12-31 | -$1.95M 10-K · filed 2026-02-25 | -$49.52M 10-K · filed 2025-02-12 | |
| 2023-12-31 | -$159.50M 10-K · filed 2026-02-25 | -$142.42M 10-K · filed 2024-02-21 | |
| 2022-12-31 | $1.10M 10-K · filed 2025-02-12 | $21.45M 10-K · filed 2023-02-16 | |
| 2021-12-31 | -$23.02M 10-K · filed 2024-02-21 | -$4.54M 10-K · filed 2022-02-16 | |
| 2020-12-31 | $11.59M 10-K · filed 2023-02-16 | ||
| 2019-12-31 | $19.88M 10-K · filed 2022-02-16 | ||
| 2018-12-31 | $28.37M 10-K · filed 2021-02-11 | ||
| 2017-12-31 | $26.77M 10-K · filed 2020-02-13 | ||
| 2016-12-31 | $35.29M 10-K · filed 2019-02-15 | ||
| 2015-12-31 | $37.31M 10-K · filed 2018-02-16 | ||
| 2014-12-31 | $11.15M 10-K · filed 2017-02-17 | ||
| 2013-12-31 | -$17.35M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |